| Ingredients: | imidacloprid, lufenuron, milbemycin oxime |
| Application: | orally |
| Type of formulation: | Insecto-acaricidal |
Description
Round- or stylised heart-shaped tablets, light lilac to purple, marbled.
Composition
1 g of the product contains the active substances:
- imidacloprid – 15,0 mg;
- lufenuron – 125,0 mg;
- milbemycin oxime – 3,75 mg.
Excipients: DL-methionine, mannitol, calcium stearate, hypromellose, microcrystalline cellulose, dried chicken meat, colorant, potato starch, lactose.
The product is available in five strengths:
PRIMERA VS (tablet mass 400 mg) – Imidacloprid 6,0 mg, Lufenuron 50,0 mg, Milbemycin oxime 1,5 mg;
PRIMERA VS (tablet mass 800 mg) – Imidacloprid 12,0 mg, Lufenuron 100,0 mg, Milbemycin oxime 3,0 mg;
PRIMERA VS (tablet mass 1,6 g) – Imidacloprid 24,0 mg, Lufenuron 200,0 mg, Milbemycin oxime 6,0 mg;
PRIMERA VS (tablet mass 3,2 g) – Imidacloprid 48,0 mg, Lufenuron 400,0 mg, Milbemycin oxime 12,0 mg;
PRIMERA VS (tablet mass 4,8 g) – Imidacloprid 72,0 mg, Lufenuron 600,0 mg, Milbemycin oxime 18,0 mg.
Pharmacological properties
ATCvet QP53, ectoparasiticides, insecticides and repellents (QP53BC51 Lufenuron, combinations).
PRIMERA VS are antiparasitic tablets used for the prevention and treatment of mixed parasitic infestations in dogs.
Imidacloprid is an ectoparasiticide belonging to the class of nitromethylene heterocyclic compounds. Imidacloprid has a high affinity for nicotinic acetylcholine receptors in postsynaptic sites of the central nervous system (CNS). It interacts with the nicotinergic receptor of the ectoparasite located on the postsynaptic neurone, disrupts transmission of the nerve impulse through it and leads to paralysis and death of the ectoparasite. Imidacloprid is effective against flea larvae and adults. Due to its weak interaction with mammalian nicotinic receptors and low penetration through the blood-brain barrier, the active substance practically does not affect the CNS of mammals.
Lufenuron belongs to the benzoylphenylurea group; it is a broad-spectrum insecticide, especially active against fleas of the species Ctenocephalides spp., Pulex irritans, and shows increased larvicidal and contact ovicidal activity. Its mechanism of action consists in blocking chitin synthesis, which is the main component of insect exoskeletons; therefore, larvae cannot form a new cuticle during moulting and die. After entering the bodies of insects with the animal’s blood and then their eggs, Lufenuron blocks the process of chitin formation; larvae die as a result of impaired cuticle formation, thus preventing the emergence of the next generation of fleas. Although it does not affect adult fleas, it prevents the development of intermediate stages of the flea life cycle (eggs, larvae, pupae).
Milbemycin oxime is a second-generation macrocyclic lactone of the milbemycin group, a compound produced by biosynthesis from Streptomyces hygroscopicus var. aureolacrimosus. Milbemycin oxime exerts a broad systemic effect on ecto- and endoparasites (insecticidal, acaricidal, nematodicidal, larvicidal, ovicidal) in dogs. Its mechanism of action in the parasite consists in stimulation of the release of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), resulting in blockade of nerve impulse transmission through the interneurones of the ventral nerve cord of nematodes and neuromuscular junctions of arthropods, which leads to paralysis and death of the parasites. Milbemycin oxime is active against adult and immature forms of Toxocara canis, Uncinaria spp., Ancylostoma spp. and their larvae (L4, L5), as well as larvae (L4) of Dirofilaria spp.
After oral administration, Imidacloprid is rapidly and almost completely absorbed from the animal’s gastrointestinal tract and reaches an effective concentration in approximately 1,3 hours. It is distributed in tissues but does not accumulate in them. Imidacloprid has a low level of penetration through the blood-brain barrier, therefore it does not affect the central nervous system of mammals. Imidacloprid is metabolised in the liver to an active metabolite and excreted in urine (70–80%) and faeces (20–30%). The terminal elimination half-life is approximately 2,2 hours.
After oral administration to animals, Lufenuron is rapidly absorbed in the stomach (maximum absorption is achieved with a stomach full of feed) and is slowly eliminated, which ensures a high concentration of the compound in the animal’s body for one month.
Milbemycin oxime is readily and rapidly absorbed systemically after oral administration, reaching maximum plasma concentration within 2–4 hours after administration and with 66,9% bioavailability. Milbemycin oxime is slowly eliminated from plasma via biliary excretion and faecal elimination, with a minor contribution of metabolic clearance.
The product is toxic to bees, as well as fish and other aquatic organisms.
Indications
Prevention and treatment of dogs in mixed parasitic infestations caused by ecto- and endoparasites:
- ixodid ticks (Dermacentor spp., Rhipicephalus spp., Ixodes spp.);
- sarcoptiform mites Otodectes cynotis and mange mites (Sarcoptes canis);
- trombidiform mites (Demodex spp.);
- fleas (Ctenocephalides spp.); including flea larvae and eggs;
- chewing lice (Trichodectes canis);
- lice (Linognathus setosus);
- nematodes of the digestive tract and respiratory tract (Toxocara canis, Toxascaris leoninа, Ancylostoma spp., Uncinaria spp., Trichuris vulpis, Strongyloides stercoralis /S. сanis, Angiostrongylus vasorum).
Prevention of flea allergy dermatitis (FAD).
Prevention of dirofilariasis: Dirofilaria spp. (microfilariae L3 and L4 stages).
Dosage and administration
PRIMERA VS is intended for oral administration (per os).
The tablets are palatable and are voluntarily consumed by most dogs. If the tablet is not voluntarily eaten, it may be given with food or directly to the animal at the root of the tongue.
It should be ensured that animals consume the full dose, and treated animals should be observed for several minutes after administration to ensure that no part of the dose is lost or rejected.
The product is administered to dogs according to the following schedule:
|
Tablet mass, g |
Body weight of animals, kg |
Active substances: Imidacloprid, mg |
Lufenuron, mg |
Milbemycin oxime, mg |
|
0,4 |
2,5–5,0 |
6 |
50 |
1,5 |
|
0,8 |
5,0–10,0 |
12 |
100 |
3,0 |
|
1,6 |
10,0–20,0 |
24 |
200 |
6,0 |
|
3,2 |
20,0–40,0 |
48 |
400 |
12,0 |
|
4,8 |
40,0–60,0 |
72 |
600 |
18,0 |
After a single administration, the antiparasitic effect lasts up to 5 weeks. In cases of flea infestation, otodectosis and ixodidosis, the tablets are administered once; to prevent reinfestation, they are administered once every 4–6 weeks throughout the entire ectoparasite activity season.
The acaricidal effect of the product appears within 24 hours; therefore, treatment should be carried out no later than 24 hours before the expected walk of the animal in areas where ticks may be present (parks, squares, forests).
The insecticidal effect of the product appears within 24 hours, reaching the maximum level after 48 hours.
In order to eliminate ectoparasites in the premises and prevent reinfection of animals, kennels, cages, bedding and blankets should be treated with an insectoacaricidal product approved for use, in accordance with the instructions for use.
In helminth infestations, for therapeutic purposes the product is administered once according to indications; in severe infestations, it is recommended to repeat treatment after 10–14 days. For prophylactic purposes, the product is administered in the therapeutic dose once every 3 months, as well as 10–14 days before each vaccination.
For the prevention of dirofilariasis in regions unfavourable for the disease, the product is used in the spring-summer-autumn period: before the beginning of mosquito and midge flight (vectors of microfilariae L3 and L4 stages), once, then once a month, and the last time in the season 1 month after the end of insect flight.
The product does not destroy sexually mature dirofilariae, but reduces the number of microfilariae circulating in the blood and may also be used in infected animals.
Contraindications
Increased individual sensitivity of the animal to the components of the product.
Do not use in sick or debilitated animals.
Do not use in animals with severe hepatic or renal impairment.
Do not use in animals under 8 weeks of age and/or weighing less than 2,5 kg.
Do not use the product together with other antiparasitic agents containing macrocyclic lactones, as well as with piperazine and cholinesterase-inhibiting products.
Do not use in females during pregnancy and lactation.
Special warnings
PRIMERA VS should be used in dogs with the ABCB1 gene mutation (MDR1 -/-) of Collies, Shetland Sheepdogs, Old English Sheepdogs and related breeds, as well as their crossbreeds only after consultation with and under the supervision of a veterinarian.
Special precautions for persons and personnel
When working with the product, observe the basic rules of hygiene and safety adopted when handling veterinary medicines.
After working with the product, wash hands with soap.
In case of accidental ingestion of the product by a person, nervous system disorders may occur; in such cases, seek medical advice immediately (have the package leaflet or product label with you).
Adverse reactions
In some animals, gastrointestinal disturbances and increased salivation, lethargy may occur, which resolve spontaneously and do not require the use of medicinal products.
Pharmaceutical form
Tablets weighing 0,4; 0,8; 1,6; 3,2 or 4,8 g, packed 1 tablet per blister. The blisters are packed 1 or 2 per carton box together with the package leaflet.
Storage
Store the product in the original packaging in a dry place, protected from light and out of the reach of children and animals, at a temperature from 0 to 25 °C.
Shelf life
3 years.
For veterinary use only!
